4/26
12:26 pm
sgmt
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity [Seeking Alpha]
Low
Report
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity [Seeking Alpha]
4/22
08:13 am
sgmt
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 [Yahoo! Finance]
Low
Report
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 [Yahoo! Finance]
4/22
08:00 am
sgmt
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Low
Report
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
4/4
08:10 am
sgmt
Sagimet Biosciences Insiders Added US$821.7k Of Stock To Their Holdings [Yahoo! Finance]
Low
Report
Sagimet Biosciences Insiders Added US$821.7k Of Stock To Their Holdings [Yahoo! Finance]
3/27
04:09 pm
sgmt
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat [Yahoo! Finance]
Medium
Report
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat [Yahoo! Finance]
3/27
04:01 pm
sgmt
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
Medium
Report
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
3/27
05:42 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Medium
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
3/26
01:56 pm
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $37.00 to $27.00. They now have a "buy" rating on the stock.
Neutral
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $37.00 to $27.00. They now have a "buy" rating on the stock.
3/25
08:01 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $26.00 price target on the stock.
Medium
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $26.00 price target on the stock.
3/25
07:05 am
sgmt
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors [Yahoo! Finance]
Medium
Report
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors [Yahoo! Finance]
3/25
07:00 am
sgmt
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
High
Report
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
3/25
06:29 am
sgmt
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates [Yahoo! Finance]
High
Report
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates [Yahoo! Finance]
3/25
06:15 am
sgmt
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
High
Report
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
3/10
08:19 pm
sgmt
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting [Yahoo! Finance]
Medium
Report
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting [Yahoo! Finance]
2/29
08:00 am
sgmt
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Medium
Report
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
2/23
05:47 am
sgmt
Painful week for retail investors invested in Sagimet Biosciences Inc. (NASDAQ:SGMT) after 22% drop, institutions also suffered losses [Yahoo! Finance]
Medium
Report
Painful week for retail investors invested in Sagimet Biosciences Inc. (NASDAQ:SGMT) after 22% drop, institutions also suffered losses [Yahoo! Finance]
2/7
11:34 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its price target lowered by analysts at JMP Securities from $47.00 to $46.00. They now have a "market outperform" rating on the stock.
Medium
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its price target lowered by analysts at JMP Securities from $47.00 to $46.00. They now have a "market outperform" rating on the stock.
2/6
01:22 pm
sgmt
Steven Cohen's Point72 Asset Management Acquires New Stake in Sagimet Biosciences Inc [Yahoo! Finance]
Medium
Report
Steven Cohen's Point72 Asset Management Acquires New Stake in Sagimet Biosciences Inc [Yahoo! Finance]